Chronic Diabetic Foot Ulcer
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Oneness BiotechTaiwan - Taipei City
2 programs1
1
Fespixon CreamPhase 41 trial
DCB-WH1 ointmentPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Oneness BiotechFespixon Cream
Oneness BiotechDCB-WH1 ointment
Clinical Trials (2)
Total enrollment: 46 patients across 2 trials
Fespixon Cream for the Treatment of Chronic Diabetic Foot Ulcers (TEXAS 1A, 2A) in Dialysis Patients
Start: Dec 2021Est. completion: Mar 20245 patients
Phase 4Completed
Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers
Start: Dec 2008Est. completion: Mar 201241 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.